Protective analgesia using bupivacaine and conventional release ibuprofen versus bupivacaine and sustained release ibuprofen for postoperative pain relief in patients undergoing third molar surgery: a randomised controlled trial. - Protective analgesia for postoperative pain relief

The University of Manchester0 个研究点目标入组 125 人开始时间: 2006年4月27日最近更新: 2019年11月25日

试验速览

暂无简介。

•1.Provision of written informed consent.
•2.Male or female outpatients scheduled for surgical removal of one or more impacted mandibular third molar, where bone
•removal is judged to be needed and, if medically indicated, removal of the ipsilateral third molar in the upper jaw (indication
•for removal according to recently published NICE guideline).
•3.Age 18 years and over.
•4.BMI no more than 35 (kgm-2).
•5.Be able and to understand and comply with all study requirements.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.History of significant psychiatric or somatic disease or other previous disease/condition or surgery which may interfere with
•the study objectives, as judged by the investigator.
•2.History of gastro-intestinal ulceration or significant dyspepsia, as judged by the investigator.
•3.History of easy bruising,bleeding, as judged by the investigator or known bleeding disorder eg haemophilia or Von
•Willebrands syndrome.
•4.Oral surgical intervention in the 30 days prior to the pre-study visit.
•5.Known hypersensitivity (ie, asthma, rhinitis, urticaria) or any form of allergic reaction to Brufen Retard(sustained release
•ibuprofen 800mg), local anaesthetic of the amide type Marcain(bupivacaine), paracetamol or any other condition where
•these drugs are contra-indicated, as judged by the investigator.

发起方